vs
Side-by-side financial comparison of InMed Pharmaceuticals Inc. (INM) and Laser Photonics Corp (LASE). Click either name above to swap in a different company.
Laser Photonics Corp is the larger business by last-quarter revenue ($919.3K vs $820.2K, roughly 1.1× InMed Pharmaceuticals Inc.). InMed Pharmaceuticals Inc. runs the higher net margin — -247.3% vs -506.4%, a 259.2% gap on every dollar of revenue. On growth, Laser Photonics Corp posted the faster year-over-year revenue change (28.3% vs -26.2%). Over the past eight quarters, Laser Photonics Corp's revenue compounded faster (-3.9% CAGR vs -16.4%).
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
IPG Photonics Corporation is a manufacturer of fiber lasers. IPG Photonics developed and commercialized optical fiber lasers, which are used in a variety of applications including materials processing, medical applications and telecommunications. IPG has manufacturing facilities in the United States, Germany, Russia and Italy.
INM vs LASE — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $820.2K | $919.3K |
| Net Profit | $-2.0M | $-4.7M |
| Gross Margin | 22.5% | -20.1% |
| Operating Margin | -247.3% | -350.0% |
| Net Margin | -247.3% | -506.4% |
| Revenue YoY | -26.2% | 28.3% |
| Net Profit YoY | 21.2% | -186.5% |
| EPS (diluted) | $-0.51 | $-0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $820.2K | — | ||
| Q3 25 | $1.1M | $919.3K | ||
| Q2 25 | $1.3M | $2.6M | ||
| Q1 25 | $1.3M | $2.3M | ||
| Q4 24 | $1.1M | $1.3M | ||
| Q3 24 | $1.3M | $716.7K | ||
| Q2 24 | $1.3M | $623.4K | ||
| Q1 24 | $1.2M | $743.0K |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $-1.7M | $-4.7M | ||
| Q2 25 | $-1.8M | $-1.8M | ||
| Q1 25 | $-2.1M | $-1.7M | ||
| Q4 24 | $-2.6M | $586.4K | ||
| Q3 24 | $-1.7M | $-1.6M | ||
| Q2 24 | $-1.9M | $-934.3K | ||
| Q1 24 | $-1.7M | $-545.7K |
| Q4 25 | 22.5% | — | ||
| Q3 25 | 36.0% | -20.1% | ||
| Q2 25 | 44.2% | 53.5% | ||
| Q1 25 | 13.9% | 49.8% | ||
| Q4 24 | 41.5% | 13.3% | ||
| Q3 24 | 39.0% | 85.0% | ||
| Q2 24 | 36.3% | 50.6% | ||
| Q1 24 | 24.7% | 51.9% |
| Q4 25 | -247.3% | — | ||
| Q3 25 | -154.2% | -350.0% | ||
| Q2 25 | -137.1% | -37.0% | ||
| Q1 25 | -168.1% | -68.7% | ||
| Q4 24 | -231.6% | -255.1% | ||
| Q3 24 | -132.7% | -238.0% | ||
| Q2 24 | -150.5% | -149.4% | ||
| Q1 24 | -146.9% | -73.8% |
| Q4 25 | -247.3% | — | ||
| Q3 25 | -154.2% | -506.4% | ||
| Q2 25 | -137.1% | -68.3% | ||
| Q1 25 | -168.1% | -73.4% | ||
| Q4 24 | -231.6% | 45.7% | ||
| Q3 24 | -132.7% | -226.8% | ||
| Q2 24 | -151.0% | -149.9% | ||
| Q1 24 | -146.9% | -73.4% |
| Q4 25 | $-0.51 | — | ||
| Q3 25 | $-0.44 | $-0.27 | ||
| Q2 25 | $-0.07 | $-0.12 | ||
| Q1 25 | $-1.94 | $-0.12 | ||
| Q4 24 | $-3.64 | $0.06 | ||
| Q3 24 | $-2.71 | $-0.13 | ||
| Q2 24 | $2.39 | $-0.09 | ||
| Q1 24 | $-3.58 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $3.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.6M | $4.1M |
| Total Assets | $11.2M | $17.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | — | ||
| Q3 25 | $9.4M | $3.6M | ||
| Q2 25 | $11.1M | $78.5K | ||
| Q1 25 | $4.7M | $179.1K | ||
| Q4 24 | $3.5M | $533.9K | ||
| Q3 24 | $5.6M | $2.1M | ||
| Q2 24 | $6.6M | $2.7M | ||
| Q1 24 | — | $5.2M |
| Q4 25 | $9.6M | — | ||
| Q3 25 | $11.6M | $4.1M | ||
| Q2 25 | $13.4M | $4.3M | ||
| Q1 25 | $7.0M | $6.8M | ||
| Q4 24 | $6.2M | $10.2M | ||
| Q3 24 | $8.4M | $9.7M | ||
| Q2 24 | $9.2M | $10.3M | ||
| Q1 24 | $11.1M | $12.4M |
| Q4 25 | $11.2M | — | ||
| Q3 25 | $13.4M | $17.5M | ||
| Q2 25 | $15.6M | $14.9M | ||
| Q1 25 | $9.3M | $16.0M | ||
| Q4 24 | $8.5M | $17.2M | ||
| Q3 24 | $10.5M | $10.6M | ||
| Q2 24 | $11.8M | $11.1M | ||
| Q1 24 | — | $13.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.4M | $763.1K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.4M | — | ||
| Q3 25 | $-1.6M | $763.1K | ||
| Q2 25 | $-1.8M | $-1.0M | ||
| Q1 25 | $-1.7M | $-1.2M | ||
| Q4 24 | $-2.5M | $-6.5M | ||
| Q3 24 | $-1.8M | $632.7K | ||
| Q2 24 | $-1.0M | $-2.4M | ||
| Q1 24 | $-1.9M | $-866.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $589.6K | ||
| Q2 24 | — | $-2.4M | ||
| Q1 24 | $-1.9M | $-1.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 82.3% | ||
| Q2 24 | — | -388.0% | ||
| Q1 24 | -165.0% | -136.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | 0.0% | 20.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -11.11× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
